Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval Despite the negative outcome, Gossamer believes seralutinib is effective in certain patients

https://www.statnews.com/2026/02/23/gossamer-drug-fails-lung-disease-study-will-still-seek-fda-approval/ By Adam FeuersteinFeb. 23, 2026 Senior Writer, Biotech